Trial NCT04466085
Publication Yang S, Lancet, 2021
Primary outcome on the report: Safety and immunogenicity.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.